TherapeuticsMD, Inc. short interest in 2025
In 2025, TherapeuticsMD, Inc.'s disclosed short interest ran from 1.51% of shares outstanding on 31 Jan 2025 to 0.54% on 31 Dec 2025, a change of -0.97 percentage points. The year's high was 1.83% on 28 Feb 2025 and its low 0.16% on 15 Jul 2025, averaging 0.72% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.61 days on 14 Feb 2025. Full history: TherapeuticsMD, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 1.51% (31 Jan 2025)
- End of year
- 0.54% (31 Dec 2025)
- Change
- -0.97 pp
- High
- 1.83% (28 Feb 2025)
- Low
- 0.16% (15 Jul 2025)
- Average
- 0.72%
- Highest days to cover
- 4.61 (14 Feb 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Jan 2025 | 1.51% | 2.67 | |
| 14 Feb 2025 | 1.35% | 4.61 | |
| 28 Feb 2025 | 1.83% | 1.00 | |
| 14 Mar 2025 | 1.48% | 2.13 | |
| 31 Mar 2025 | 1.46% | 2.98 | 10-K filed, results (8-K) |
| 15 Apr 2025 | 1.27% | 4.42 | |
| 30 Apr 2025 | 1.02% | 3.11 | |
| 15 May 2025 | 0.78% | 1.71 | 10-Q filed, results (8-K) |
| 30 May 2025 | 0.72% | 3.64 | |
| 13 Jun 2025 | 0.36% | 1.00 | |
| 30 Jun 2025 | 0.20% | 1.00 | |
| 15 Jul 2025 | 0.16% | 1.00 | |
| 31 Jul 2025 | 0.18% | 1.00 | |
| 15 Aug 2025 | 0.21% | 1.26 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 0.17% | 1.54 | |
| 15 Sep 2025 | 0.33% | 1.83 | |
| 30 Sep 2025 | 0.34% | 3.01 | |
| 15 Oct 2025 | 0.30% | 1.69 | |
| 14 Nov 2025 | 0.60% | 1.00 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 0.49% | 1.00 | |
| 15 Dec 2025 | 0.58% | 1.03 | |
| 31 Dec 2025 | 0.54% | 1.21 |
See also: TherapeuticsMD, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.